Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals
September 1, 2026
Vertex Pharmaceuticals Incorporated completed its acquisition of Crinetics Pharmaceuticals, Inc. on September 1, 2026, in a transaction valued at approximately $10 billion in equity value. The acquisition adds PALSONIFY, atumelnant and other pipeline programs, establishing rare endocrine diseases as a new growth area for Vertex.
- Targets
- Crinetics Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B
July 5, 2026
Pharmaceuticals
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for total equity value of about $10 billion ($8.8 billion net of estimated cash acquired). The deal—priced at $85 per share—was announced as a definitive agreement and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.
-
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
April 6, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.
-
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics
January 26, 2026
Healthcare Services
BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).
-
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences
April 10, 2024
Biotechnology
Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.
-
Vertex Pharmaceuticals Acquires ViaCyte for $320M
July 11, 2022
Biotechnology
Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.
-
Chimerix Acquires Oncoceutics
January 7, 2021
Biotechnology
Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.